Molecular docking and spectroscopic exploration (FT‐IR, FT‐Raman) with HOMO–LUMO, ADMET, and 5,7‐dihydroxy‐2‐(4‐hydroxyphenyl) chroman‐4‐one against lung cancer: A potential uptake B‐RAF inhibitor

Abstract Naringenin has been proven to inhibit cell proliferation, which has anticancer properties. The role of Naringenin molecule in lung cancer and its processes are yet unknown. Naringenin is chemically called as 5,7‐dihydroxy‐2‐(4‐hydroxyphenyl) chroman‐4‐one, which was optimized geometrical parameters analysis such as bond length, bond angle and torsion angle were analyzed from Naringenin by utilizing Gaussian 09 W program. Characterizations of Naringenin analyzed by B3LYP density functional theory with basis set 6–311G (d,p). The energy value of Naringenin molecules are analyzed with (ground state) HOMO value −4.616, LUMO value for −0.169 (first excited state) energies and also predicted by energy cap value is 4.446. ADMET and drug likeness of the title compound was predicted, it's qualified with the Lipinski's rule of five. Naringenin molecular structural changes, distribution and also its reactive site investigated with MEP (Molecular Electrostatic Potential) analyses spans from −0.118eO to 0.118eO. The density of state (DOS) used to know molecular orbital contribution for selected compound. It was determined that Naringenin molecule in the active site of B‐RAF inhibitor (PDB code: 4MNF) has a binding energy of −8.9 based on a docking analysis and conformational changes. From this study, this drug will be expected to undergo essential future chemotherapy agent for lung cancer patient.